Hypothesis

In aged skin and joint tissues, oxidative stress upregulates HYAL2, which cleaves high‑molecular‑weight hyaluronan (HA) at the plasma membrane to release ~20 kDa fragments. These fragments are not merely inflammatory agonists; they penetrate the cell, accumulate in lysosomes, cause lysosomal membrane permeabilization, release cathepsins, and activate the NLRP3 inflammasome. The resulting caspase‑1–dependent processing of IL‑1β and IL‑18 fuels a senescence‑associated secretory phenotype (SASP) that reinforces fibroblast and chondrocyte senescence. This positions lysosomal rupture as the mechanistic bridge between HA fragmentation and cellular senescence, a link absent from current literature.

Mechanistic rationale

• ROS → HYAL2 ↑ → HA fragmentation: Reactive oxygen species both directly depolymerize HA and increase HYAL2 transcription/activity 1.4‑1.7‑fold via p38MAPK [4], generating ~20 kDa HA oligomers that accumulate in the pericellular space [1].
• Fragment uptake and lysosomal targeting: Low‑MW HA binds CD44 and RHAMM, triggering clathrin‑mediated endocytosis. Once internalized, the ~20 kDa HA is routed to lysosomes where its high negative charge and small size destabilize the lysosomal membrane, a property demonstrated for other glycosaminoglycans [5] but not yet tested for HA fragments.
• Lysosomal rupture → NLRP3 activation: Cathepsin B release into the cytosol is a canonical NLRP3 trigger. We hypothesize that cathepsin B released from HA‑damaged lysosomes binds NLRP3, leading to ASC speck formation, caspase‑1 cleavage, and maturation of IL‑1β/IL‑18.
• Inflammasome → SASP → senescence: IL‑1β signaling autocrinely reinforces NF‑κB activity, sustains p16^INK4a^ expression, and drives the SASP, which in turn remodels the extracellular matrix and perpetuates a senescent state in fibroblasts and chondrocytes [6]

This model extends the existing view that HA fragments act solely through surface receptors (CD44/RHAMM) by introducing an intracellular danger‑signal pathway that directly couples enzymatic HA breakdown to the senescence program.

Predictions and experimental design

1. Fragment size dictates lysosomal impact

   • Treat primary human dermal fibroblasts and articular chondrocytes with defined HA fractions ( >1000 kDa, 500‑200 kDa, ~20 kDa, <5 kDa). Measure lysosomal integrity using Galectin‑3 puncta formation and cathepsin B release (immunofluorescence and western blot). Expect ~20 kDa HA to cause significant lysosomal permeabilization, whereas >500 kDa HA will not.

2. HYAL2 dependence

   • Use siRNA or CRISPRi to knock down HYAL2 in cells exposed to H2O2 (to mimic oxidative stress). Quantify extracellular ~20 kDa HA by ELISA‑based HA size assay and assess lysosomal rupture and inflammasome activation (ASC specks, caspase‑1 activity). Prediction: HYAL2 loss will blunt both lysosomal damage and NLRP3 signaling despite ROS presence.

3. NLRP3 requirement for senescence

   • Pharmacologically inhibit NLRP3 (MCC950) or genetically delete NLRP3 in the same cells. Read out SASP cytokines (IL‑1β, IL‑6, IL‑8) via ELISA and senescence markers (SA‑β‑gal, p16^INK4a^, p21). Prediction: NLRP3 blockade will attenuate SASP and reduce senescence marker accumulation even when ~20 kDa HA is present.

4. In vivo validation

   • Inject fluorescently labeled ~20 kDa HA into murine dorsal skin or knee joint. Co‑inject a lysosomal‑stabilizing agent (e.g., chloroquine low dose) or an NLRP3 inhibitor. After 7‑14 days, assess tissue sections for lysosomal rupture (LAMP1 loss), caspase‑1 activation, and senescent cell burden (p16^INK4a^ immunostaining). Expect that stabilizing lysosomes or blocking NLRP3 will diminish senescence markers despite HA fragment presence.

Falsifiability

If ~20 kDa HA fails to induce lysosomal permeabilization, or if lysosomal stabilization does not reduce inflammasome activation and senescence in the presence of HA fragments, the hypothesis would be refuted. Likewise, if HYAL2 knockdown does not lower fragment levels yet senescence still occurs via an alternative ROS‑driven pathway, the proposed causal chain would be incomplete.

By linking enzymatic HA turnover to intracellular danger signaling, this hypothesis redirects focus from anabolic HAS2 loss to catabolic HYAL2‑driven lysosomal injury as a central driver of age‑related tissue dysfunction.